EC Microbiology

Review Article Volume 22 Issue 2 - 2026

Biomarkers of Ebola Vaccine Efficacy and Safety: Comprehensive Review

Abubakar Yaro1,2,3*, Mohammed Faleh Alqahtani4 and Jean Bangura2

1AHRO Institute, Department of Translational and Clinical Research, Stevenage, UK

2Africa Health Research Organization, Accra, Ghana

3Dr Yaro Laboratory, Kano, Nigeria

4King Khalid University Medical City, Abha, Saudi Arabia

*Corresponding Author: Abubakar Yaro, AHRO Institute, Department of Translational and Clinical Research, Stevenage, UK and Africa Health Research Organization, Accra, Ghana and Dr Yaro Laboratory, Kano, Nigeria.
Received: December 12, 2025; Published: January 28, 2026



Ebola virus is one of the most devastating viruses that belong to the Filoviridae. An outbreak of Ebola virus infection is associated with high mortality rates as evidenced during the West Africa outbreak. Although there are no effective antiviral agents against Ebola viral disease, there has been progress in the development of EBOV-associated vaccines. One of the challenges of deploying these vaccines in outbreaks is measuring the correlation of protection as a result of administration of the vaccine. Developing novel biomarkers to measure this correlation would go a long way to develop effective preventive and management strategies. Immune responses in response to EBOV vaccine can be standardised and developed as novel biomarkers. For effective utilization of these biomarkers, developing biomarkers which can be universally utilized should be a priority.

 Keywords: Ebola Virus, Vaccine; Therapeutic; Biomarkers; Clinical Trial

  1. Malvy D., et al. “Ebola virus disease”. The Lancet10174 (2019): 936-948.
  2. Bukreyev AA., et al. “Discussions and decisions of the 2012-2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012-June 2013”. Archives of Virology 4 (2013): 821-830.
  3. Bosa HK., et al. “The west Africa Ebola virus disease outbreak: 10 years on”. The Lancet7 (2024): e1081-e1083.
  4. Leligdowicz A., et al. “Ebola virus disease and critical illness”. Critical Care1 (2016): 217.
  5. Mupapa K., et al. “Ebola hemorrhagic fever and pregnancy”. Journal of Infectious Diseases 1 (1999): S11-S12.
  6. Rajek A., et al. “Insights from clinical research completed during the west Africa Ebola virus disease epidemic”. Lancet Infectious Diseases 9 (2017): e280-e292.
  7. Ramharter M and Gunther S. “Evaluating case definitions for Ebola virus disease”. Lancet Infectious Diseases 11 (2020): 1224-1226.
  8. Caleo G., et al. “Clinical and epidemiological performance of WHO Ebola case definitions: a systematic review and meta-analysis”. Lancet Infectious Diseases 11 (2020): 1324-1338.
  9. Martin P., et al. “Laboratory diagnosis of Ebola virus disease”. Intensive Care Medicine 5 (2015): 895-898.
  10. “Clinical management of patients with viral hemorrhagic fever: a pocket guide for the front-line health workers”. Geneva, Switzerland WHO (2014).
  11. Tomori O and Kolawole MO. “Ebola virus disease: current vaccine solutions”. Current Opinion in Immunology 71 (2021): 27-33.
  12. Falzarano D., et al. “Progress in filovirus vaccine development: evaluating the potential for clinical use”. Expert Review of Vaccines 1 (2011): 63-77.
  13. Clark DK., et al. “Safety and immunogenicity of a highly attenuated rVSVN4CTs-EBOVGP1 Ebola virus vaccine: a randomized, double-blind, placebo-controlled, phase 1 clinical trial”. Lancet Infectious Diseases 4 (2020): 455-466.
  14. Henoa-Restrepo AM., et al. “Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: interim results from the Guinea ring vaccination, open-label, cluster-randomised trial”. Lancet 9996 (2015): 857-866.
  15. Henao-Restrepo AM., et al. “Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised train”. Lancet10068 (2017): 505-518.
  16. Regules JA., et al. “A recombinant vesicular stomatitis virus Ebola vaccine”. New England Journal of Medicine 4 (2017): 330-341.
  17. Feldmann H., et al. “Ebola: Lessons on vaccine development”. Annual Review of Microbiology 72 (2018): 423-446.
  18. Woolsey C and Geisbert TW. “Current state of Ebola virus vaccines: A snapshot”. PLoS Pathogen12 (2021): e1010078.
  19. Ebola Vaccine Team B, Wellcome Trust, CIDRAP. “Completing the Development of Ebola vaccine: current status, Remaining challenges, and Recommendations” (2017).
  20. Custers J., et al. “Vaccine based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment”. Vaccine22 (2021): 3081-3091.
  21. Milligen ID., et al. “Safety and immunogenicity of novel adenovirus type 26-modified vaccinia Ankara-vectored ebola vaccines: a randomised clinical trial”. Journal of the American Medical Association15 (2016): 1610-1623.
  22. Ewer K., et al. “A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA”. New England Journal of Medicine 17 (2016): 1635-1646.
  23. Tapia MD., et al. “Use of ChAd3-EBO-Z virus vaccine in Malian and US adults, and boosting of Malain adults with MVA-BN-Filo: a phase 1, single-blind, randomised trail, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial”. Lancet Infectious Diseases 1 (2016): 31-42.
  24. Dolzhikova IV., et al. “Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5- vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia”. Human Vaccines and Immunotherapeutics 3 (2017): 613-620.
  25. Matunvanga TZ., et al. “Setting-up an Ebola vaccine trial in a remote area of the Democratic Republic of Congo: challenges, mitigation, and lessons learned”. Vaccine25 (2022): 3470-3480.
  26. Lariviere Y., et al. “Open-label, randomised, clinical trial to evaluate the immunogenicity and safety of a prophylactic vaccination of healthcare providers by administration of a heterologous vaccine regimen against Ebola in the Democratic Republic of the Congo: the study protocol”. BMJ Open9 (2021): e046835.
  27. Pollard AJ., et al. “Safety and immunogenicity of a two-dose heterologus Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2) a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial”. Lancet Infectious Diseases 4 (2021): 493-506.
  28. Kibuuka H., et al. “Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomized, double-blind, placebo-controlled clinical trial”. Lancet9977 (2015): 1545-1554.
  29. Li J-X., et al. “Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial”. Lancet Global Health 3 (2017): e324-e334.
  30. Zhu F-C, Hou LH., et al. “Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomized, double-blind, placebo-controlled, phase 1 trial”. Lancet9984 (2015): 2272-2279.
  31. Ishola D., et al. “Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial”. Lancet Infectious Diseases 1 (2022): 97-109.
  32. Afolabi MO., et al. “Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial”. Lancet Infectious Diseases 1 (2022): 110-122.
  33. Mooney T., et al. “EBOVAC-Salone: Lessons learned from implementing an Ebola vaccine trial in an Ebola-affected country”. Clinical Trials 5 (2018): 436-443.
  34. Van Thilbeurgh M., et al. “Predictive markers of immunogenicity and efficacy for human vaccines”. Vaccines6 (2021): 579.
  35. Aronson JK. “Research priorities in biomarkers and surrogate end-points”. British Journal of Clinical Pharmacology 6 (2012): 900-907.
  36. Zhu Y., et al. “Toward the development of monoclonal antibody-based assays to probe virion-like epitopes in hepatitis B vaccine antigen”. Human Vaccines and Immunotherapeutics 4 (2014): 1013-1023.
  37. Huang Y., et al. “Simultaneous evaluation of the magnitude and breadth of a left and right censored multivariate response, with application to HIV vaccine development”. Statistics in Biopharmaceutical Research 1 (2009): 81-91.
  38. Poestsch JH., et al. “Detectable Vesicular Stomatitis virus (VSV)-specific humoral and cellular immune responses following VSV-Ebola Virus vaccination”. Journal of Infectious Diseases 4 (2019): 556-561.
  39. Van Tilbeurgh M., et al. “Predictive markers of immunogenicity and efficacy for human vaccines”. Vaccines (Basel) 6 (2021): 579.
  40. DeGottardi Q., et al. “Ontogeny of different subsets of yellow fever virus-specific circulatory CXCR+ CD4+ T cell after yellow fever vaccination”. Scientific Reports1 (2020): 15686.
  41. Baloh CH., et al. “Biomarkers detected in cord blood predict vaccine responses in young infants”. Frontiers in Immunology 14 (2023): 1152538.
  42. Weinberg A., et al. “Varicella-Zoster virus-specific immune responses to Herpes Zoster in elderly participants in a trial of the clinically effective Zoster vaccine”. Journal of Infectious Diseases 7 (2009): 1068-1077.
  43. Moss B. “Smallpox vaccines: targets of protective immunity”. Immunological Review1 (2011): S8-S26.
  44. Julkunen I., et al. “Antibody responses to mumps virus proteins in natural mumps infection and after vaccination with live and inactivated mumps virus vaccines”. Journal of Medical Virology 3 (1984): 209-219.
  45. Monath TP. “Yellow fever: an update”. Lancet Infectious Diseases 1 (2001): P11-P20.
  46. Darrah PA., et al. “Prevention of tuberculosis in macaques after intravenous BCG immunization”. Nature 577 (2020): 95-102.
  47. Pattyn J., et al. “Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature”. Papillomavirus Research 8 (2019): 100185.
  48. Rivera A and Messaoudi I. “Molecular mechanisms of Ebola pathogenesis”. Journal of Leukocyte Biology 5 (2016): 889-904.
  49. Follman D. “Augmented designs to assess immune response in vaccine trials”. Biometric4 (2006): 1161-1169.
  50. Apostolopoulos V and Marincola FM. “Methods to measure vaccine immunity”. Expert Review of Vaccines 6 (2010): 545-546.
  51. Bannister S., et al. “The emerging role of epigenetic in the immune response to vaccination and infection: a systematic review”. Epigenetic 6-7 (2020): 555-593.
  52. Haq K and EmElhaney JE. “Immunosenescence: influenza vaccination and the elderly”. Current Opinion in Immunology 29 (2014): 38-42.
  53. Gensous N., et al. “Responders and non-responders to influenza vaccination: A DNA methylation approach on blood cells”. Experimental Gerontology 105 (2018): 94-100.
  54. Plotkin SA and Gilbert PB. “Nomenclature for immune correlates of protection after vaccination”. Clinical Infectious Diseases11 (2012): 1615-1617.
  55. Alexandre M., et al. “Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola”. NPJ Vaccine1 (2023): 174.
  56. Roozendaal R., et al. “Nonhuman primate to human innunobridging to infer the protective effect of an Ebola virus vaccine candidate”. NPJ Vaccine1 (2020): 112.
  57. Xu Z., et al. “A mathematical model simulating the adaptive immune response in various vaccines and vaccination strategies”. Scientific Reports 1 (2024): 23995.
  58. Xu Z., et al. “A novel mathematical model that predicts the protection time of SARS-CoV-2 antibodies”. Viruses 2 (2023): 586.
  59. Nakamura N., et al. “Modeling and predicting individual variation in COVID-19 vaccine-elicited antibody response in the general population”. PLOS Digital Health5 (2024): e0000497.
  60. De Pillis L., et al. “A mathematical model of the within-host kinetics of SARS-CoV-2 neutralizing antibodies following COVID-19 vaccination”. Journal of Theoretical Biology 556 (2023): 111280.
  61. Russell TW., et al. “Real-time estimation of immunological response against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study”. Lancet Infectious Diseases 1 (2025): P80-P93.
  62. De Santis O., et al. “Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study”. Lancet Infectious Diseases 3 (2016): 311-320.
  63. Lambe T., et al. “Detection of vaccine-induced antibodies to Ebola virus in oral fluid”. Open Forum Infectious Diseases 1 (2016): ofw031.
  64. Ewer K., et al. “A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA”. New England Journal of Medicine17 (2016): 1635-1640.
  65. Milligan ID., et al. “Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: A randomized clinical trial”. Journal of the American Medical Association 15 (2016): 1610-1623.
  66. Winslow RL., et al. “Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored Ebola vaccines at 1 year”. Journal of the American Medical Association 10 (2017): 1075-1077.
  67. Rechtien A., et al. “Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the Ebola vaccine rVSV-ZEBOV”. Cell Reports9 (2017): 2251-2261.
  68. Meyer M., et al. “Can Ebola Virus vaccine have a universal immune correlates of protection?” Trends in Microbiology 1 (2019): 8-16.

Abubakar Yaro., et al. “Biomarkers of Ebola Vaccine Efficacy and Safety: Comprehensive Review”. EC Microbiology  22.2 (2026): 01-13.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net